We are live on ! Find out more
MEDP icon

Medpace

462 hedge funds and large institutions have $5.78B invested in Medpace in 2023 Q2 according to their latest regulatory filings, with 86 funds opening new positions, 167 increasing their positions, 148 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 38

66% more call options, than puts

Call options by funds: $21.2M | Put options by funds: $12.8M

60% more funds holding in top 10

Funds holding in top 10: 58 (+3)

23% more capital invested

Capital invested by funds: $4.68B → $5.78B (+$1.1B)

13% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 148

11% more funds holding

Funds holding: 415462 (+47)

1.95% less ownership

Funds ownership: 81.08%79.13% (-1.9%)

Holders
462
Holders Change
+47
Holders Change %
+11.33%
% of All Funds
7.24%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.13%
New
86
Increased
167
Reduced
148
Closed
38
Calls
$21.2M
Puts
$12.8M
Net Calls
+$8.41M
Net Calls Change
+$12.1M

MEDP Hedge Fund Activity: Q2 2023 in Review

462 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Medpace (MEDP) for Q2 2023, worth a combined $5.78B — up 23% from $4.68B a quarter earlier.

Buyers outnumbered sellers: 86 funds opened new MEDP positions and 38 closed out — a net gain of 48 holders — while 167 added to existing stakes and 148 trimmed.

The largest buyer was Riverbridge Partners, adding an estimated $43.8M. The largest seller was BlackRock, cutting an estimated $146M.

  • 462 institutional investors held Medpace (MEDP) as of Q2 2023, up from 415 in Q1 2023.
  • Funds reported $5.78B of Medpace stock for Q2 2023, up 23% quarter-over-quarter.
  • 86 funds opened new Medpace positions in Q2 2023 and 38 closed out, a net change of +48 holders.
  • The largest Medpace buyer in Q2 2023 was Riverbridge Partners, an estimated $43.8M added.
  • The largest Medpace seller in Q2 2023 was BlackRock, an estimated $146M sold.

Based on aggregated 13F filings for Q2 2023.